New drugs for weight loss in patients with type 2 diabetes

Dror Dicker

Dr Dror Dicker is the head of the Department of Internal Medicine at the Rabin Medical Center (Israel) and co-chair of the Obesity Management Task Force of the European Association for the Study of Obesity.

Are there any new drugs that could be used in patients with type 2 diabetes mellitus to reduce weight?

Dror Dicker, MD: We have 2 main drug families that deal with weight loss and diabetes. The first is glucagon-like peptide 1 (GLP-1) receptor analogues, which work by reducing hunger and increasing satiety. We know from functional magnetic resonance imaging (MRI) that GLP-1 analogues affect the hypothalamus but also higher cognitive centers. The net effect is increasing satiety, reducing hunger, and looking on food in a very different way.

The second family is sodium-glucose cotransporter 2 (SGLT-2) inhibitors, which secrete carbohydrates, secrete glucose in urine, and by doing so they are reducing calories every day. But this is a little bit complicated, because there is a higher level of glucagon and greater hunger for carbohydrates with SGLT-2, so the net effect is around 3- to 4-kg weight loss. With a GLP-1 analogue, we see a higher reduction of weight, around 5% to 6%.

These 2 drug families that treat diabetes can also help in weight loss. If we have people with obesity and type 2 diabetes and we are concerned with their weight, according to the new guidelines we should use first GLP-1 analogues that are proven to reduce weight, and then, if we need better control of the glucose level, we can add SGLT-2.

From my experience the combinations of GLP-1 analogues and SGLT-2 are synergistic, because the GLP-1 analogue blunts the hunger for carbohydrates from SGLT-2. So it is a synergistic effect of these 2 antidiabetic and also weight-loss promoting medications.

See also

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.